Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial

Jörres, Achim; Gahl, Gerhard M.; Dobis, Clemens; Polenakovič, Momir; Cakalaroski, K; Rutkowski, Bolesław; Kisielnicka, Ewa; Krieter, Detlef H.; Rumpf, K. W.; Guenther, C; Gaus, Wilhelm; Hoegel, Josef

doi:10.1016/s0140-6736(99)01213-1

Cited by 128 publications

(61 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have compared the impact of these two membrane types on mortality among patients with AKI. Six RCTs showed no significant differences in mortality or recovery of renal function between BCM and BICM [56][57][58][59][60][61]. Thus, KDIGO clinical practice guidelines for acute kidney injury have recommended BCM for IHD and CRRT in patients with AKI [20].…”

Section: Dialysis Membranes For Rrt In Patients With Akimentioning

confidence: 99%

Renal replacement therapy for acute kidney injury

et al. 2016

View full text Add to dashboard Cite

The annual incidence of acute kidney injury (AKI) has been increasing as the population ages. Despite advances in critical care and dialysis technology, the mortality remains unacceptably high in patients with AKI during the past few decades. Renal replacement therapy (RRT) is performed to treat patients with severe AKI and multiple organ failures, as well as to remove fluid in patients with fluid overload including those with acute heart failure and lung edema in the intensive care unit (ICU). The mortality in patients with AKI requiring RRT is higher than 50 %. RRT strategies in patients with AKI depend on various conditions. However, there is little consensus on when to start and stop RRT, its optimal dose, and the choice of different RRT modalities (intermittent versus (vs.) continuous) in patients with AKI. Patients with AKI in the ICU are preferentially treated with continuous rather than intermittent RRT (IRRT), usually because of hemodynamic stability and steady of solute clearance. At present, the type and dose of RRT are dependent on the experience of the attending clinicians, including intensivists and nephrologists.

show abstract

Section: Dialysis Membranes For Rrt In Patients With Akimentioning

confidence: 99%

Renal replacement therapy for acute kidney injury

et al. 2016

View full text Add to dashboard Cite

show abstract

“…La méthodologie de l'étude est critiquable (26 patients seulement randomisés dans chaque groupe) mais les résultats ont été confirmés par deux autres groupes [20,34]. Cependant, d'autres observations, toujours chez le patient en dialyse intermittente, réalisées sur un grand nombre de sujets, ont abouti à des conclusions différentes [35][36][37]. Chaque étude a évidemment ses limitations méthodologiques et certains conflits d'intérêt ont même parfois été évoqués (études soutenues par les fabricants de membranes) [38,39].…”

Section: Quelle Membrane Favoriser ?unclassified

“…Sur la base de l'ensemble des études et de deux méta-analyses [40,41], on peut toutefois affirmer que l'utilisation d'une membrane en cuprophane ne doit plus être recommandée pour la dialyse des patients aux soins intensifs. En revanche, il ne semble pas y avoir de grandes différences entre les membranes synthétiques et les membranes en cellulose modifiée [1,20,[33][34][35][36][37]40].…”

Section: Quelle Membrane Favoriser ?unclassified

L'épuration extrarénale appliquée au patient hospitalisé aux soins intensifs

Delanaye¹,

Dubois

Lambermont

et al. 2007

Néphrologie & Thérapeutique

View full text Add to dashboard Cite

RésuméLa mortalité reste élevée chez les patients de soins intensifs chez qui un traitement de suppléance rénale est nécessaire. Dans cet article, nous faisons le point sur les données récentes de la littérature qui améliorent la prise en charge de tels patients. Nous discutons successivement du choix du mode d'épuration (intermittente ou continue), de la membrane, de la dose à prescrire, du type d'anticoagulation et du moment où débuter la suppléance.Mots clés : anticoagulation ; épuration extrarénale ; hémodialyse ; hémofiltration ; membrane ; soins intensifs AbstractMortality remains high in intensive care patients with renal failure requiring extra corporeal blood purification. This article reviews the recent data that have led to the improvement of the care for such patients. We will discuss the criteria to determine the choice of the technique (intermittent or continuous), of the membrane, of the prescribing dose, and the type of anticoagulation and when to initiate such a treatment.

show abstract

“…middle molecules, hydrophobic substances and protein (albumin) bound materials (Krieter et al, 2005;Ahrenholz et al, 2004;Ronco et al, 1999;Kim, 1994;Testa et al, 2006;Meyer et al, 2005;Mandolfo et al, 2006;Kanter et al, 2008). In the presence of ultrapure dialysis fluid which is ultrafiltrated by endotoxin restraint systems (Weber et al, 2000;Canaud et al, 2001;Minetti et al, 1985;Hakim et al, 1984) and biocompatible high flux dialysis membranes the convective diffusive treatment significantly prevents the complement activation (Braun et al, 1995;Savica et al, 2006;Jorres et al, 1999;Hörl et al, 1986) in the first minutes of olHDF session and removes proinflammatory substances (cytokines) too (Bellomo et al, 1991;Filiopoulos et al, 2008;Haas et al, 2007;Libetta et al, 2007;Mariano et al, 2005). The intra and interdialytic inflammations are reduced (Ramirez et al, 2007;Ramirez et al, 2007;Carracedo et al, 2006).…”

Section: Introductionmentioning

confidence: 99%